Liquidia Corporation (NASDAQ: LQDA) Stock Competitors & Peer Comparison

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, RPRX has a market cap of 25.9B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while RPRX trades at $58.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas RPRX's P/E ratio is 11.13. In terms of profitability, LQDA's ROE is +1.50%, compared to RPRX's ROE of +0.12%. Regarding short-term risk, LQDA is more volatile compared to RPRX. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check RPRX's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CORT has a market cap of 12.3B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CORT trades at $113.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CORT's P/E ratio is 325.03. In terms of profitability, LQDA's ROE is +1.50%, compared to CORT's ROE of +0.08%. Regarding short-term risk, LQDA is less volatile compared to CORT. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CORT's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, WBA has a market cap of 10.4B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while WBA trades at $11.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas WBA's P/E ratio is -1.64. In terms of profitability, LQDA's ROE is +1.50%, compared to WBA's ROE of -0.57%. Regarding short-term risk, LQDA is more volatile compared to WBA. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check WBA's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, KNSA has a market cap of 6B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while KNSA trades at $78.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas KNSA's P/E ratio is 80.55. In terms of profitability, LQDA's ROE is +1.50%, compared to KNSA's ROE of +0.14%. Regarding short-term risk, LQDA is less volatile compared to KNSA. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check KNSA's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, PBH has a market cap of 2.2B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while PBH trades at $46.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas PBH's P/E ratio is 10.59. In terms of profitability, LQDA's ROE is +1.50%, compared to PBH's ROE of +0.09%. Regarding short-term risk, LQDA is less volatile compared to PBH. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check PBH's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, HROWL has a market cap of 1.4B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while HROWL trades at $25.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas HROWL's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to HROWL's ROE of -1.04%. Regarding short-term risk, LQDA is more volatile compared to HROWL. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check HROWL's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, HROWM has a market cap of 1.3B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while HROWM trades at $26.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas HROWM's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to HROWM's ROE of -1.04%. Regarding short-term risk, LQDA is more volatile compared to HROWM. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check HROWM's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, LTGO has a market cap of 1.3B. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while LTGO trades at $21.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas LTGO's P/E ratio is -11.41. In terms of profitability, LQDA's ROE is +1.50%, compared to LTGO's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to LTGO. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check LTGO's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, HELP has a market cap of 846.7M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while HELP trades at $13.66.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas HELP's P/E ratio is -3.28. In terms of profitability, LQDA's ROE is +1.50%, compared to HELP's ROE of -0.71%. Regarding short-term risk, LQDA is less volatile compared to HELP. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check HELP's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SVA has a market cap of 464.9M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SVA trades at $6.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SVA's P/E ratio is -5.68. In terms of profitability, LQDA's ROE is +1.50%, compared to SVA's ROE of -0.01%. Regarding short-term risk, LQDA is more volatile compared to SVA. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check SVA's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, ETRA has a market cap of 295.3M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while ETRA trades at $13.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas ETRA's P/E ratio is -5.25. In terms of profitability, LQDA's ROE is +1.50%, compared to ETRA's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to ETRA. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check ETRA's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CUVL has a market cap of 293.5M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CUVL trades at $5.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CUVL's P/E ratio is 12.56. In terms of profitability, LQDA's ROE is +1.50%, compared to CUVL's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to CUVL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CUVL's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CELG-RI has a market cap of 254.5M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CELG-RI trades at $0.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to CELG-RI's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CELG-RI's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, HITI has a market cap of 231.1M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while HITI trades at $2.63.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas HITI's P/E ratio is -9.71. In terms of profitability, LQDA's ROE is +1.50%, compared to HITI's ROE of -0.36%. Regarding short-term risk, LQDA is more volatile compared to HITI. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check HITI's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CTOR has a market cap of 97.2M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CTOR trades at $1.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CTOR's P/E ratio is -2.22. In terms of profitability, LQDA's ROE is +1.50%, compared to CTOR's ROE of -1.03%. Regarding short-term risk, LQDA is less volatile compared to CTOR. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CTOR's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, ATLN has a market cap of 73.2M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while ATLN trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas ATLN's P/E ratio is -0.68. In terms of profitability, LQDA's ROE is +1.50%, compared to ATLN's ROE of -83.20%. Regarding short-term risk, LQDA is less volatile compared to ATLN. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check ATLN's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SDEV has a market cap of 49.1M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SDEV trades at $0.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SDEV's P/E ratio is -0.17. In terms of profitability, LQDA's ROE is +1.50%, compared to SDEV's ROE of +7.90%. Regarding short-term risk, LQDA is less volatile compared to SDEV. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SDEV's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, RAD has a market cap of 36.8M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while RAD trades at $0.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas RAD's P/E ratio is -0.05. In terms of profitability, LQDA's ROE is +1.50%, compared to RAD's ROE of +2.76%. Regarding short-term risk, LQDA is less volatile compared to RAD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check RAD's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, GLTO has a market cap of 34.5M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while GLTO trades at $21.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas GLTO's P/E ratio is -1.78. In terms of profitability, LQDA's ROE is +1.50%, compared to GLTO's ROE of -0.83%. Regarding short-term risk, LQDA is less volatile compared to GLTO. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check GLTO's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, NSRX has a market cap of 29.6M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while NSRX trades at $3.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas NSRX's P/E ratio is -4.78. In terms of profitability, LQDA's ROE is +1.50%, compared to NSRX's ROE of -1.59%. Regarding short-term risk, LQDA is less volatile compared to NSRX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check NSRX's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SCYX has a market cap of 27.7M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SCYX trades at $4.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SCYX's P/E ratio is -1.29. In terms of profitability, LQDA's ROE is +1.50%, compared to SCYX's ROE of -0.21%. Regarding short-term risk, LQDA is less volatile compared to SCYX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SCYX's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, COSM has a market cap of 18.4M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while COSM trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas COSM's P/E ratio is -0.46. In terms of profitability, LQDA's ROE is +1.50%, compared to COSM's ROE of -1.19%. Regarding short-term risk, LQDA is less volatile compared to COSM. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check COSM's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, BFRI has a market cap of 14.9M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while BFRI trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas BFRI's P/E ratio is -2.11. In terms of profitability, LQDA's ROE is +1.50%, compared to BFRI's ROE of -1.28%. Regarding short-term risk, LQDA is less volatile compared to BFRI. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check BFRI's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CNSY has a market cap of 13.1M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CNSY trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CNSY's P/E ratio is -0.45. In terms of profitability, LQDA's ROE is +1.50%, compared to CNSY's ROE of -3.94%. Regarding short-term risk, LQDA is less volatile compared to CNSY. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CNSY's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SCNX has a market cap of 12.4M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SCNX trades at $0.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SCNX's P/E ratio is -0.15. In terms of profitability, LQDA's ROE is +1.50%, compared to SCNX's ROE of -0.54%. Regarding short-term risk, LQDA is less volatile compared to SCNX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SCNX's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, BFRIW has a market cap of 11.6M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while BFRIW trades at $0.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas BFRIW's P/E ratio is -0.03. In terms of profitability, LQDA's ROE is +1.50%, compared to BFRIW's ROE of -1.28%. Regarding short-term risk, LQDA is more volatile compared to BFRIW. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check BFRIW's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CJJD has a market cap of 9.9M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CJJD trades at $1.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CJJD's P/E ratio is -0.46. In terms of profitability, LQDA's ROE is +1.50%, compared to CJJD's ROE of -0.25%. Regarding short-term risk, LQDA is less volatile compared to CJJD. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check CJJD's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SSY has a market cap of 7.9M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SSY trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SSY's P/E ratio is -2.86. In terms of profitability, LQDA's ROE is +1.50%, compared to SSY's ROE of -0.09%. Regarding short-term risk, LQDA is less volatile compared to SSY. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check SSY's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, POM has a market cap of 5.4M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while POM trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas POM's P/E ratio is -0.13. In terms of profitability, LQDA's ROE is +1.50%, compared to POM's ROE of +0.16%. Regarding short-term risk, LQDA is less volatile compared to POM. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check POM's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, BGMS has a market cap of 5.3M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while BGMS trades at $0.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas BGMS's P/E ratio is -0.27. In terms of profitability, LQDA's ROE is +1.50%, compared to BGMS's ROE of -0.32%. Regarding short-term risk, LQDA is less volatile compared to BGMS. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check BGMS's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, EOCN has a market cap of 3.6M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while EOCN trades at $3.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas EOCN's P/E ratio is -0.25. In terms of profitability, LQDA's ROE is +1.50%, compared to EOCN's ROE of N/A. Regarding short-term risk, LQDA is less volatile compared to EOCN. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check EOCN's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, PAVS has a market cap of 3.5M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while PAVS trades at $4.06.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas PAVS's P/E ratio is -0.05. In terms of profitability, LQDA's ROE is +1.50%, compared to PAVS's ROE of -0.46%. Regarding short-term risk, LQDA is less volatile compared to PAVS. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check PAVS's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, MDVL has a market cap of 2.9M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while MDVL trades at $1.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas MDVL's P/E ratio is -0.05. In terms of profitability, LQDA's ROE is +1.50%, compared to MDVL's ROE of -2.39%. Regarding short-term risk, LQDA is less volatile compared to MDVL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check MDVL's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, ATNFW has a market cap of 2.6M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while ATNFW trades at $0.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas ATNFW's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to ATNFW's ROE of -2.15%. Regarding short-term risk, LQDA is less volatile compared to ATNFW. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check ATNFW's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, BGMSP has a market cap of 2.4M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while BGMSP trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas BGMSP's P/E ratio is -0.84. In terms of profitability, LQDA's ROE is +1.50%, compared to BGMSP's ROE of -0.32%. Regarding short-term risk, LQDA is less volatile compared to BGMSP. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check BGMSP's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, AZNH has a market cap of 1.6M. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while AZNH trades at $53.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas AZNH's P/E ratio is 38.35. In terms of profitability, LQDA's ROE is +1.50%, compared to AZNH's ROE of +0.00%. Regarding short-term risk, LQDA is more volatile compared to AZNH. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check AZNH's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, LFLYW has a market cap of 299.9K. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while LFLYW trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas LFLYW's P/E ratio is -0.00. In terms of profitability, LQDA's ROE is +1.50%, compared to LFLYW's ROE of +0.42%. Regarding short-term risk, LQDA is more volatile compared to LFLYW. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check LFLYW's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, PRPH has a market cap of 148.9K. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while PRPH trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas PRPH's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to PRPH's ROE of -13.59%. Regarding short-term risk, LQDA is less volatile compared to PRPH. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check PRPH's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, CPD has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while CPD trades at $5.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas CPD's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to CPD's ROE of N/A. Regarding short-term risk, LQDA is more volatile compared to CPD. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check CPD's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, SHPG has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while SHPG trades at $179.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas SHPG's P/E ratio is 11.35. In terms of profitability, LQDA's ROE is +1.50%, compared to SHPG's ROE of +0.13%. Regarding short-term risk, LQDA is more volatile compared to SHPG. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check SHPG's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, POZN has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while POZN trades at $5.94.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas POZN's P/E ratio is N/A. In terms of profitability, LQDA's ROE is +1.50%, compared to POZN's ROE of +0.61%. Regarding short-term risk, LQDA is less volatile compared to POZN. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check POZN's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, OREX has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while OREX trades at $0.22.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas OREX's P/E ratio is -0.14. In terms of profitability, LQDA's ROE is +1.50%, compared to OREX's ROE of -0.54%. Regarding short-term risk, LQDA is less volatile compared to OREX. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check OREX's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, IPXL has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while IPXL trades at $18.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas IPXL's P/E ratio is -10.11. In terms of profitability, LQDA's ROE is +1.50%, compared to IPXL's ROE of -1.16%. Regarding short-term risk, LQDA is less volatile compared to IPXL. This indicates lower risk in terms of short-term price fluctuations for LQDA.Check IPXL's competition here

Liquidia Corporation (NASDAQ: LQDA) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, LQDA stands at 5.9B. In comparison, ESRX has a market cap of 0. Regarding current trading prices, LQDA is priced at $66.43 on the NASDAQ, while ESRX trades at $92.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

LQDA currently has a P/E ratio of 48.49, whereas ESRX's P/E ratio is 10.69. In terms of profitability, LQDA's ROE is +1.50%, compared to ESRX's ROE of +0.26%. Regarding short-term risk, LQDA is more volatile compared to ESRX. This indicates higher risk in terms of short-term price fluctuations for LQDA.Check ESRX's competition here